Image Source: Pixabay

The 5 constituents in the munKNEE Psychedelic Drug Stocks Index are ranked below in descending order as to their performances as of October 13th, and since the end of July.

1. Incannex Healthcare (IXHL): down 6.4% this week (-4.4% last week); down 43.6% since July
   • is researching and developing therapies and products with the world's largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.
   • Read:
     • Incannex to Prepare FDA IND Application for Psilocybin-assisted Psychedelic Psychotherapy Program, Known as Psi-GAD
     • Review of IND Application for IHL-42X by US FDA has been completed; Clinical Trial for Patients with Obstructive Sleep Apnoea May Proceed
2. Atai (ATAI): down 7.9% this week (+17.8% last week); down 38.8% since July
   • is focused on the use of ketamine, DMT and ibogaine.  Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
   • Read:
     • atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants
     • atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)
3. GH Research (GHRS): down 9.0% this week (-10.3% last week); down 39.7% since July
   • is primarily focused on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine.
   • Read:
     • GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression
     • GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates
4. Mind Medicine (MNMD): down 9.4% this week (-1.6% last week); down 43.2% since July
   • is primarily focused on the use of LSD and MNMA. Go here for much more extensive information on LSD and  here for much more extensive information on MNMA.
   • Read:
     • MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
     • MindMed Reports Second Quarter 2023 Financial Results and Business Highlights
5. Compass Pathways (CMPS): down 12.9% this week (-7.4% last week); down 35.7% since July
   • is focused on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
   • Read:
     • COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression
     • COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights

Summary

The munKNEE Psychedelic Drug Stocks Index was down 10.1% this week (-6.3% last week) and is now down 39.2% since July.

More By This Author:

Micro/Small Cap AI Stocks Index Is Still Up 110% YTD
Cannabis Stocks Continued To Decline, On Average, This Week
Interested In AI? These 7 Mega-Caps Dominate All Facets Of Its Development